LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website: https://business.uoregon.edu/centers/lce

Clinical Trials

The Significance of Funguria in Hospitalized Patients

Completed

Conditions: Urinary Tract Infections

First Posted Date: 2008-11-07

Last Posted Date: 2008-11-07

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 919

Registration Number: NCT00787085

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Clinical Trial of Growth Hormone in MPS I, II, and VI

Phase 2

Terminated

Conditions: Mucopolysaccharidosis VI
Mucopolysaccharidosis I
Mucopolysaccharidosis II

Interventions: Drug: Somatropin (DNA origin)

First Posted Date: 2008-09-09

Last Posted Date: 2018-09-05

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 2

Registration Number: NCT00748969

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section

Phase 4

Completed

Conditions: Contraception

Interventions: Device: Copper IUD ( ParaGard Intrauterine Contraceptive Device)

First Posted Date: 2008-08-13

Last Posted Date: 2014-08-11

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 7

Registration Number: NCT00733278

Locations: 🇺🇸
Los Angeles BRI, Torrance, California, United States

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

Phase 3

Completed

Conditions: Surgical Site Infection
Late Effects of Surgery
Staphylococcus Aureus

Interventions: Drug: daptomycin

First Posted Date: 2008-06-19

Last Posted Date: 2016-08-29

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 30

Registration Number: NCT00701636

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

Arterial pH and Total Body Nitrogen Balances in APD

Phase 4

Completed

Conditions: End-stage Renal Disease

Interventions: Drug: ammonium chloride or sodium citrate/citric acid
Drug: Sodium citrate/citratic acid

First Posted Date: 2008-01-04

Last Posted Date: 2017-09-05

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 8

Registration Number: NCT00586131

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

L-Glutamine Therapy for Sickle Cell Anemia

Phase 2

Terminated

Conditions: Sickle Cell Anemia
Thalassemia

Interventions: Drug: L-Glutamine
Drug: Placebo

First Posted Date: 2008-01-04

Last Posted Date: 2021-02-02

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 15

Registration Number: NCT00586209

Locations: 🇺🇸
LA Biomed at Harbor-UCLA Medical Center, Torrance, California, United States

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

Phase 3

Completed

Conditions: Hypoalbuminemia
Protein-energy Malnutrition
Inflammation
Oxidative Stress
Chronic Kidney Disease (CKD) Hemodialysis

Interventions: Drug: pentoxiphylline
Dietary Supplement: Nepro
Dietary Supplement: Placebo to imitate Nepro
Dietary Supplement: anti-inflammatory module (similar to Oxepa)
Drug: Placebo pill imitating pentoxiphylline
Dietary Supplement: Placebo to imitate anti-inflammatory module (similar to Oxepa)

First Posted Date: 2007-11-20

Last Posted Date: 2015-05-21

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 93

Registration Number: NCT00561093

Locations: 🇺🇸
Los Angeles Biomedical Research Institute (LABioMed) at Harbor-UCLA, Torrance, California, United States
🇺🇸
DaVita Nutrition Services, Irvine, California, United States

A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection

Phase 3

Completed

Conditions: Methicillin Resistant Staphylococcus Aureus Skin Infections

Interventions: Drug: mupirocin and chlorhexidine
Drug: mupirocin, chlorhexidine, & household cleaning/disinfection
Behavioral: household cleaning and disinfection

First Posted Date: 2007-11-20

Last Posted Date: 2013-09-26

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 350

Registration Number: NCT00560599

Locations: 🇺🇸
Kaiser Permanente, Harbor City, Harbor City, California, United States
🇺🇸
Kaiser Permanente, Panorama City, Panorama City, California, United States
🇺🇸
Kaiser Permanente, Bellflower, Bellflower, California, United States

and more 3 locations

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

Phase 2

Completed

Conditions: Mucormycosis

Interventions: Drug: deferasirox
Drug: Placebo
Drug: Liposomal amphotericin B

First Posted Date: 2007-01-09

Last Posted Date: 2023-10-16

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 20

Registration Number: NCT00419770

Locations: 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 4 locations

A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers

Phase 2

Completed

Conditions: Infected Corneal Ulcers
Bacterial Keratitis
Corneal Ulcer
Childhood Blindness

First Posted Date: 2006-10-12

Last Posted Date: 2016-08-23

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 172

Registration Number: NCT00386958

Locations: 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy